The Role of Short Course of High-Dose Methylprednisolone in Children with Acute Myeloblastic Leukemia (FAB M2) Presented with Myeloid Tumor
| Autor: | Deniz Aslan, Gönül Hiçsönmez, Emel Ozyurek, Mualla Cetin |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Acute myeloblastic leukemia medicine.drug_class medicine.medical_treatment Antineoplastic Agents Methylprednisolone Drug Administration Schedule Antigens CD Oral administration hemic and lymphatic diseases medicine Humans Sarcoma Myeloid Child Chemotherapy business.industry Bone Marrow Examination Cell Differentiation Hematology medicine.disease Leukemia Myeloid Acute Steroid hormone Treatment Outcome medicine.anatomical_structure Oncology Apoptosis Child Preschool Pediatrics Perinatology and Child Health Immunology Cancer research Corticosteroid Female Bone marrow business medicine.drug |
| Zdroj: | Pediatric Hematology and Oncology. 20:373-379 |
| ISSN: | 1521-0669 0888-0018 |
| DOI: | 10.1080/08880010390203954 |
| Popis: | The authors have previously demonstrated a favorable effect of high-dose methylprednisolone (HDMP), which can induce differentiation and apoptosis of leukemic cells in children with acute myeloblastic leukemia (AML). Here, they evaluate the effect of short-course HDMP in 2 children with acute myeloblastic leukemia (AML-M2) presented with myeloid tumor (MT). Methylprednisolone (20 or 30 mg/kg/day) was given orally, in a single dose, without using other antileukemic agents. Rapid cytoreduction in MT, peripheral blood, and bone marrow blasts was observed in both children following short-course (4 or 7 days) HDMP treatment, possibly due to HDMP-induced differentiation and apoptosis of leukemic cells. The effects of HDMP should be explored in patients with other subtypes of AML who present with MT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|